TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.

Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.

There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.


Options:
A: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
B: Arm Label: sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: FAI insert; Type: EXPERIMENTAL; Interventions: Drug: FAI insert | Intervention Type: DRUG; Name: FAI insert; Assigned to Arm(s): FAI insert | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): sham injection
C: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg
D: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.

Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.

There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.


Options:
A: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
B: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.


Options:
A: Arm Label: Audit + Feedback; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit + Feedback | Arm Label: Audit + Feedback + Educational Outreach; Type: EXPERIMENTAL; Interventions: Behavioral: Audit + Feedback, Behavioral: Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback; Assigned to Arm(s): Audit + Feedback, Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback + Educational Outreach; Assigned to Arm(s): Audit + Feedback + Educational Outreach
B: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Communication, Behavioral: Systematic Pain Assessment and Treatment, Behavioral: Medication Review, Behavioral: Occupational therapy, Behavioral: Safety | Intervention Type: BEHAVIORAL; Name: Communication; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Systematic Pain Assessment and Treatment; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Medication Review; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Occupational therapy; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Safety; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.


Options:
A: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Arm Label: Brexpiprazole 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole, OPC-34712 | Arm Label: Brexpiprazole 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole, OPC-34712 | Intervention Type: DRUG; Name: Brexpiprazole, OPC-34712; Assigned to Arm(s): Brexpiprazole 1 mg, Brexpiprazole 2 mg | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pimavanserin 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pimavanserin tartrate | Intervention Type: DRUG; Name: Pimavanserin tartrate; Assigned to Arm(s): Pimavanserin 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Study to learn if the alternate formulation is effective in agitated schizophrenic patients


Options:
A: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Intramuscular Olanzepine 10 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
D: Arm Label: ALKS 9072; Type: EXPERIMENTAL; Interventions: Drug: ALKS 9072 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ALKS 9072; Assigned to Arm(s): ALKS 9072 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Study to learn if the alternate formulation is effective in agitated schizophrenic patients


Options:
A: Arm Label: clozapine; Type: EXPERIMENTAL; Interventions: Drug: Clozapine | Arm Label: Olanzapine; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine | Arm Label: Haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Intervention Type: DRUG; Name: Clozapine; Assigned to Arm(s): clozapine | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): Haloperidol
B: Intervention Type: DRUG; Name: Intramuscular Olanzepine 10 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
D: Arm Label: Intramuscular ziprasidone; Type: EXPERIMENTAL; Interventions: Drug: Intramuscular ziprasidone mesylate | Arm Label: Intramuscular haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intramuscular haloperidol | Intervention Type: DRUG; Name: Intramuscular ziprasidone mesylate; Assigned to Arm(s): Intramuscular ziprasidone | Intervention Type: DRUG; Name: Intramuscular haloperidol; Assigned to Arm(s): Intramuscular haloperidol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.


Options:
A: Arm Label: Cohort 1: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Cohort 2: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Cohort 3: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Open Label; Type: OTHER; Interventions: Drug: Anti-IP-10 Antibody | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Induction, Cohort 2: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Cohort 1: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Cohort 2: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Open Label
B: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: Budesonide MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: Budesonide MMX® 9 mg | Arm Label: 3: Entocort EC® 3 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Entocort EC® 3 mg | Arm Label: 4: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Entocort EC® 3 mg, 4: Placebo | Intervention Type: DRUG; Name: Budesonide MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: Budesonide MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Entocort EC® 3 mg; Assigned to Arm(s): 3: Entocort EC® 3 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4: Placebo
C: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
D: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: sterile saline for injection | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MDX-1100 | Intervention Type: BIOLOGICAL; Name: sterile saline for injection; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MDX-1100; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (control procedure) | Arm Label: Epidural injection of etanercept; Type: EXPERIMENTAL; Interventions: Drug: epidural injection of etanercept | Intervention Type: DRUG; Name: epidural injection of etanercept; Assigned to Arm(s): Epidural injection of etanercept | Intervention Type: DRUG; Name: placebo (control procedure); Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.


Options:
A: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
B: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 9 mg | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Arm Label: 4: Asacol® 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Asacol® 400 mg | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Placebo, 4: Asacol® 400 mg | Intervention Type: DRUG; Name: budesonide-MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: budesonide-MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3: Placebo | Intervention Type: DRUG; Name: Asacol® 400 mg; Assigned to Arm(s): 4: Asacol® 400 mg
C: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
D: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.


Options:
A: Arm Label: Adalimumab 80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 160/80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80/40 | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160/80/40 | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1 (i); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2 (ii); Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 (i), 2 (ii)
C: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Golimumab 100 mg -> 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 50 mg | Arm Label: Golimumab 200 mg -> 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Golimumab 400 mg -> 200 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 200 mg, Biological: Golimumab 400 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg, Golimumab 200 mg -> 100 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): Golimumab 200 mg -> 100 mg, Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 400 mg; Assigned to Arm(s): Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Study of Lopinavir/Ritonavir in HIV-1 Infected Infants Less Than 6 Months of Age
Brief Summary: The purpose of this study is to find out if the drug lopinavir/ritonavir (LPV/RTV) is safe and well tolerated in HIV infected infants. This study will also determine the most effective dose of LPV/RTV for infants.


Options:
A: Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abacavir, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nelfinavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abacavir, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nelfinavir, Drug: Nevirapine, Drug: Zidovudine | Intervention Type: DRUG; Name: Abacavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nelfinavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): 1, 2
C: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
D: Intervention Type: DRUG; Name: nevirapine; Assigned to Arm(s): N/A

Answer: A